Morgan Stanley’s Fennec Pharmaceuticals FENC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.39M | Buy |
221,920
+10,812
| +5% | +$88.3K | ﹤0.01% | 4739 |
|
|
2026
Q1 | $1.3M | Sell |
211,108
-31,368
| -13% | -$242K | ﹤0.01% | 5015 |
|
|
2025
Q4 | $1.87M | Buy |
242,476
+10,074
| +4% | +$82.7K | ﹤0.01% | 4859 |
|
|
2025
Q3 | $2.18M | Sell |
232,402
-21,816
| -9% | -$189K | ﹤0.01% | 4725 |
|
|
2025
Q2 | $2.11M | Sell |
254,218
-42,395
| -14% | -$290K | ﹤0.01% | 4666 |
|
|
2025
Q1 | $1.81M | Sell |
296,613
-49,763
| -14% | -$320K | ﹤0.01% | 4672 |
|
|
2024
Q4 | $2.19M | Buy |
346,376
+197,914
| +133% | +$1.01M | ﹤0.01% | 4631 |
|
|
2024
Q3 | $742K | Buy |
148,462
+46,377
| +45% | +$268K | ﹤0.01% | 5215 |
|
|
2024
Q2 | $624K | Buy |
102,085
+27,995
| +38% | +$232K | ﹤0.01% | 5190 |
|
|
2024
Q1 | $824K | Sell |
74,090
-3,049
| -4% | -$30.6K | ﹤0.01% | 5073 |
|
|
2023
Q4 | $866K | Buy |
77,139
+34,679
| +82% | +$287K | ﹤0.01% | 4998 |
|
|
2023
Q3 | $319K | Sell |
42,460
-18,198
| -30% | -$148K | ﹤0.01% | 5369 |
|
|
2023
Q2 | $536K | Buy |
60,658
+2,485
| +4% | +$20.7K | ﹤0.01% | 5178 |
|
|
2023
Q1 | $484K | Buy |
58,173
+12,797
| +28% | +$119K | ﹤0.01% | 5277 |
|
|
2022
Q4 | $436K | Buy |
45,376
+9,314
| +26% | +$82.4K | ﹤0.01% | 5311 |
|
|
2022
Q3 | $292K | Sell |
36,062
-4,279
| -11% | -$29.4K | ﹤0.01% | 5547 |
|
|
2022
Q2 | $225K | Sell |
40,341
-9,839
| -20% | -$57.1K | ﹤0.01% | 5838 |
|
|
2022
Q1 | $281K | Buy |
50,180
+9,171
| +22% | +$46.2K | ﹤0.01% | 5729 |
|
|
2021
Q4 | $180K | Buy |
41,009
+26
| +0.1% | +$194 | ﹤0.01% | 6128 |
|
|
2021
Q3 | $386K | Sell |
40,983
-2,447
| -6% | -$18.4K | ﹤0.01% | 5648 |
|
|
2021
Q2 | $316K | Buy |
43,430
+2,453
| +6% | +$16.4K | ﹤0.01% | 5778 |
|
|
2021
Q1 | $255K | Sell |
40,977
-17,052
| -29% | -$128K | ﹤0.01% | 5512 |
|
|
2020
Q4 | $431K | Buy |
58,029
+14,206
| +32% | +$108K | ﹤0.01% | 5170 |
|
|
2020
Q3 | $266K | Buy |
43,823
+21,070
| +93% | +$149K | ﹤0.01% | 4956 |
|
|
2020
Q2 | $190K | Buy |
+22,753
| New | +$169K | ﹤0.01% | 5095 |
|
|
2020
Q1 | – | Sell |
-400
| Closed | -$3K | – | 6608 |
|
|
2019
Q4 | $3K | Buy |
400
+399
| +39,900% | +$2.14K | ﹤0.01% | 6457 |
|
|
2019
Q3 | $0 | Sell |
1
-141
| -99% | -$622 | ﹤0.01% | 6671 |
|
|
2019
Q2 | $1K | Sell |
142
-3,393
| -96% | -$14.4K | ﹤0.01% | 6534 |
|
|
2019
Q1 | $17K | Sell |
3,535
-18,651
| -84% | -$123K | ﹤0.01% | 6055 |
|
|
2018
Q4 | $142K | Sell |
22,186
-1,802
| -8% | -$12.6K | ﹤0.01% | 5418 |
|
|
2018
Q3 | $196K | Sell |
23,988
-2,317
| -9% | -$21.5K | ﹤0.01% | 5460 |
|
|
2018
Q2 | $275K | Buy |
26,305
+24,439
| +1,310% | +$290K | ﹤0.01% | 5410 |
|
|
2018
Q1 | $23K | Buy |
1,866
+1,500
| +410% | +$14.2K | ﹤0.01% | 6095 |
|
|
2017
Q4 | $4K | Buy |
+366
| New | +$3.65K | ﹤0.01% | 6360 |
|
Other funds holding FENC
RA
ACM
SCM
AIC
PCA
Morgan Stanley's FENC Position: Q2 2026 in Review
Morgan Stanley increased its Fennec Pharmaceuticals (FENC) stake by 5.1% in Q2 2026, buying an estimated $88.3K and bringing the position to 221,920 shares worth $2.39M. The position accounts for ﹤0.01% of the portfolio, ranked #4739.
Morgan Stanley first reported a position in FENC in Q4 2017 and has held it in 34 quarters since. 105 funds tracked by Wall St. Rank hold FENC as of Q2 2026.
- Morgan Stanley held 221,920 shares of Fennec Pharmaceuticals worth $2.39M as of Q2 2026.
- Morgan Stanley bought 10,812 Fennec Pharmaceuticals shares in Q2 2026, an estimated $88.3K.
- Fennec Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4739 holding.
- Morgan Stanley first reported a position in Fennec Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- 105 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.